Tebapivat

Phase 2Small molecule

AAgios Pharmaceuticals, Inc.

Tebapivat is one of 79 small molecule programs targeting Myelodysplastic Syndromes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromesActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Adakveo

Novartis

Phase 3

7 2

Exjade

Novartis

Phase 3

4 3

Brilinta

AstraZeneca

Phase 3

3 4

Campath

GGenzyme, a Sanofi Company

Phase 3

12 5

Ritalin

Novartis

Phase 3

2 6

Cysteine Hydrochloride

Novartis

Phase 3

2 7

Oxbryta

GGlobal Blood Therapeutics

Phase 3

5 8

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 9

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

3 10

Xarelto

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Sickle Cell Disease

NCT06924970

Q1 2029

Phase 2Active, not recruiting

Myelodysplastic Syndromes

NCT05490446

Clinical

Trials by Indication[1]

Sickle Cell Disease1 trial

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Recruiting·AAgios Pharmaceuticals, Inc.·Phase 2·NCT06924970·56 enrolled

Myelodysplastic Syndromes1 trial

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes

Active, not recruiting·AAgios Pharmaceuticals, Inc.·Phase 2·NCT05490446·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tebapivat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tebapivat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tebapivat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Agios Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAgios Pharmaceuticals, Inc.

Tebapivat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2029

Trials by Indication[1]

Sickle Cell Disease1 trial

Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News